GAITHERSBURG, Md.--Sequenom has installed its MassArray system at the US National Cancer Institute’s Advanced Technology Center here for use in analysis of single-nucleotide polymorphisms that occur in genes involved with cancer and other diseases. The system combines Sequenom’s proprietary enzymology and bioinformatics in a miniaturized chip-based format with mass spectrometry technology. The deal marks the third installation by the German company of its MassArray system in the US, and the fifth worldwide.
The cancer institute also recently licensed pharmaco-genomics tools from Genomica. Genomica’s CEO Theresa Ayers said her company’s Discovery Manager tool will enable the institute to integrate the data in its bioinformatics pipeline, from pedigree information to the linkage analysis and sequence analysis stages of disease studies.